These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18324929)

  • 61. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes.
    Gavi S; Stuart LM; Kelly P; Melendez MM; Mynarcik DC; Gelato MC; McNurlan MA
    J Clin Endocrinol Metab; 2007 May; 92(5):1886-90. PubMed ID: 17299074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice.
    Zemany L; Bhanot S; Peroni OD; Murray SF; Moraes-Vieira PM; Castoldi A; Manchem P; Guo S; Monia BP; Kahn BB
    Diabetes; 2015 May; 64(5):1603-14. PubMed ID: 25524914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.
    Graham TE; Yang Q; Blüher M; Hammarstedt A; Ciaraldi TP; Henry RR; Wason CJ; Oberbach A; Jansson PA; Smith U; Kahn BB
    N Engl J Med; 2006 Jun; 354(24):2552-63. PubMed ID: 16775236
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
    Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
    Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retinol-binding protein 4 as a risk factor for cholesterol gallstone formation.
    Han T; Zhang D; Fu Z; Sun Y; Yang W; Yuan C
    Mol Cell Biochem; 2013 May; 377(1-2):219-27. PubMed ID: 23420326
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass.
    Klöting N; Graham TE; Berndt J; Kralisch S; Kovacs P; Wason CJ; Fasshauer M; Schön MR; Stumvoll M; Blüher M; Kahn BB
    Cell Metab; 2007 Jul; 6(1):79-87. PubMed ID: 17618858
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
    Kubota N; Terauchi Y; Kubota T; Kumagai H; Itoh S; Satoh H; Yano W; Ogata H; Tokuyama K; Takamoto I; Mineyama T; Ishikawa M; Moroi M; Sugi K; Yamauchi T; Ueki K; Tobe K; Noda T; Nagai R; Kadowaki T
    J Biol Chem; 2006 Mar; 281(13):8748-55. PubMed ID: 16431926
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
    Hiramatsu S; Tajiri Y; Karashima T
    Diabetes Obes Metab; 2004 May; 6(3):231-3. PubMed ID: 15056132
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma.
    Kageyama H; Hirano T; Okada K; Ebara T; Kageyama A; Murakami T; Shioda S; Adachi M
    Biochem Biophys Res Commun; 2003 May; 305(1):22-7. PubMed ID: 12732191
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    Ramachandran A; Snehalatha C; Salini J; Vijay V
    J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
    Emilsson V; O'Dowd J; Wang S; Liu YL; Sennitt M; Heyman R; Cawthorne MA
    Metabolism; 2000 Dec; 49(12):1610-5. PubMed ID: 11145125
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
    Yamasaki Y; Kawamori R; Wasada T; Sato A; Omori Y; Eguchi H; Tominaga M; Sasaki H; Ikeda M; Kubota M; Ishida Y; Hozumi T; Baba S; Uehara M; Shichiri M; Kaneko T
    Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
    Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
    Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.
    Yang Q; Graham TE; Mody N; Preitner F; Peroni OD; Zabolotny JM; Kotani K; Quadro L; Kahn BB
    Nature; 2005 Jul; 436(7049):356-62. PubMed ID: 16034410
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
    Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
    Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
    Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
    Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.